公开(公告)号：US11179355B2

公开(公告)日：2021-11-23

申请号：US15042906

申请日：2016-02-12

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K31/165 ,  A61K9/00 ,  A61K31/24 ,  C07C279/14 ,  A61K31/16 ,  C07C237/22 ,  A61K45/06 ,  A61K47/54

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

公开(公告)号：US20150297736A1

公开(公告)日：2015-10-22

申请号：US14692526

申请日：2015-04-21

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K47/48 ,  A61K31/485

CPC classification number: A61K47/48023 ,  A61K9/51 ,  A61K31/485 ,  A61K47/4813 ,  A61K47/48246 ,  A61K47/54 ,  A61K47/555 ,  A61K47/64 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/5088 ,  G01N33/9486 ,  G01N2333/976 ,  G01N2500/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

Abstract translation: 提供了药物组合物及其使用方法，其中药物组合物包含提供阿片样物质的酶控释放的阿片样前体药物和与介导阿片样物质的酶控释放的酶相互作用的酶抑制剂 来自阿片样前药，以减轻阿片样物质前药的酶切。

公开(公告)号：US09040032B2

公开(公告)日：2015-05-26

申请号：US13686725

申请日：2012-11-27

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K31/74 ,  A61K47/48 ,  A61K9/51 ,  A61K31/485 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/50 ,  G01N33/94

CPC classification number: A61K47/48023 ,  A61K9/51 ,  A61K31/485 ,  A61K47/4813 ,  A61K47/48246 ,  A61K47/54 ,  A61K47/555 ,  A61K47/64 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/5088 ,  G01N33/9486 ,  G01N2333/976 ,  G01N2500/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

Abstract translation: 提供了药物组合物及其使用方法，其中药物组合物包含提供阿片样物质的酶控释放的阿片样前体药物和与介导阿片样物质的酶控释放的酶相互作用的酶抑制剂 来自阿片样前药，以减轻阿片样物质前药的酶切。

公开(公告)号：US20150031635A1

公开(公告)日：2015-01-29

申请号：US14320351

申请日：2014-06-30

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: C07K5/072 ,  A61K31/55 ,  A61K31/495 ,  A61K31/485 ,  C07D217/04 ,  C07D221/26 ,  A61K31/451 ,  A61K31/445 ,  A61K31/195 ,  C07C279/18 ,  A61K31/155 ,  C07C215/64 ,  C07D295/185 ,  C07D211/66 ,  C07C257/18 ,  C07D491/08 ,  A61K31/135 ,  C07D223/04 ,  A61K31/439 ,  A61K38/05

CPC classification number: C07K5/06121 ,  A61K31/135 ,  A61K31/155 ,  A61K31/195 ,  A61K31/439 ,  A61K31/445 ,  A61K31/451 ,  A61K31/485 ,  A61K31/495 ,  A61K31/55 ,  A61K38/05 ,  A61K47/50 ,  A61K47/54 ,  A61K47/543 ,  A61K47/56 ,  C07C215/64 ,  C07C257/18 ,  C07C279/18 ,  C07C2603/80 ,  C07D211/66 ,  C07D217/04 ,  C07D221/26 ,  C07D223/04 ,  C07D295/185 ,  C07D491/08

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Abstract translation: 提供了药物组合物及其使用方法，其中药物组合物包含提供酚类阿片样物质的酶控释放的酚类阿片样物质前药，以及与介导酶促控制释放的酶相互作用的酶抑制剂 来自前药的酚类阿片样物质，以减轻前药的酶裂解。

公开(公告)号：US20160235694A1

公开(公告)日：2016-08-18

申请号：US15042906

申请日：2016-02-12

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K31/165 ,  A61K9/00 ,  A61K31/24

CPC classification number: A61K31/165 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/16 ,  A61K31/24 ,  A61K45/06 ,  A61K47/542 ,  A61K47/543 ,  C07C237/22 ,  C07C279/14 ,  A61K2300/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

公开(公告)号：US20130210700A1

公开(公告)日：2013-08-15

申请号：US13686710

申请日：2012-11-27

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K47/48 ,  A61K31/485

CPC classification number: C12Q1/37 ,  A61K31/485 ,  A61K47/556

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.

Abstract translation: 提供了药物组合物及其使用方法，其中药物组合物包含提供酚类阿片样物质的酶控释放的酚修饰的阿片样物质前药，以及与介导酶控制的酶相互作用的酶抑制剂 从苯酚修饰的阿片样物质前药释放酚类阿片样物质，以改变苯酚修饰的阿片样物质前药的酶裂解。

公开(公告)号：US09585963B2

公开(公告)日：2017-03-07

申请号：US14692526

申请日：2015-04-21

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K31/74 ,  A61K47/48 ,  A61K9/51 ,  A61K31/485 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/50 ,  G01N33/94

CPC classification number: A61K47/48023 ,  A61K9/51 ,  A61K31/485 ,  A61K47/4813 ,  A61K47/48246 ,  A61K47/54 ,  A61K47/555 ,  A61K47/64 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/5088 ,  G01N33/9486 ,  G01N2333/976 ,  G01N2500/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

Abstract translation: 提供了药物组合物及其使用方法，其中药物组合物包含提供阿片样物质的酶控释放的阿片样前体药物和与介导阿片样物质的酶控释放的酶相互作用的酶抑制剂 来自阿片样前药，以减轻阿片样物质前药的酶切。

公开(公告)号：US20130210854A1

公开(公告)日：2013-08-15

申请号：US13708486

申请日：2012-12-07

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K9/00 ,  C07D489/08

CPC classification number: A61K9/0002 ,  A61K31/485 ,  A61K38/00 ,  A61K47/556 ,  C07D489/02 ,  C07D489/08 ,  C07K5/06078 ,  C07K5/06095 ,  C12Q1/37

Abstract: The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.

Abstract translation: 本公开提供了药物组合物及其使用方法，其中药物组合物包含提供酶控制释放的药物的前体药物和与介导酶控释放的酶的酶抑制剂相互作用的酶抑制剂 来自前药的药物，以减轻前药的酶裂解。 本公开提供了药物组合物，其包含酶抑制剂和前体药物，其包含可切割的部分，其在被切割时促进药物的释放。

公开(公告)号：US20130210701A1

公开(公告)日：2013-08-15

申请号：US13686725

申请日：2012-11-27

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K47/48 ,  A61K31/485

CPC classification number: A61K47/48023 ,  A61K9/51 ,  A61K31/485 ,  A61K47/4813 ,  A61K47/48246 ,  A61K47/54 ,  A61K47/555 ,  A61K47/64 ,  C07D489/02 ,  C07D489/08 ,  C12Q1/37 ,  G01N33/5088 ,  G01N33/9486 ,  G01N2333/976 ,  G01N2500/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.

公开(公告)号：US20200253900A1

公开(公告)日：2020-08-13

申请号：US16656409

申请日：2019-10-17

Applicant: Signature Therapeutics, Inc.

Inventor： Thomas E. Jenkins ,  Craig O. Husfeld ,  Julie D. Seroogy ,  Jonathan W. Wray

IPC: A61K31/165 ,  A61K47/54 ,  A61K45/06 ,  C07C237/22 ,  A61K31/16 ,  C07C279/14 ,  A61K31/24 ,  A61K9/00

Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.